Press Releases April 28, 2026 06:30 AM

BOSS Zhipin's Ongoing Share Repurchases Reach Nearly RMB1.07 Billion in 2026

KANZHUN LIMITED Continues Aggressive Share Buyback Program, Spending Nearly RMB1.07 Billion in 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED (traded as BZ on Nasdaq) has continued its share repurchase program with a recent buyback of approximately RMB27.3 million for 588,046 shares. The company has consistently repurchased shares for 26 trading days and has spent nearly RMB1.07 billion on buybacks so far in 2026, signaling strong commitment to enhancing shareholder value.

BOSS Zhipin's Ongoing Share Repurchases Reach Nearly RMB1.07 Billion in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has repurchased shares for 26 consecutive trading days in 2026.
  • The company has spent nearly RMB1.07 billion on share repurchases year-to-date.
  • The latest buyback involved approximately RMB27.3 million for 588,046 ordinary shares.

BEIJING, April 28, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB27.3 million to repurchase 588,046 ordinary shares on April 27. With this latest transaction, the Company has made repurchases for the past 26 consecutive trading days, deploying nearly RMB1.07 billion toward share repurchases year-to-date in 2026. This effort underscores the Company's ongoing commitment to delivering value to shareholders.


Risks

  • Continued large share buybacks may strain company cash reserves or impact liquidity.
  • Market or regulatory changes could affect the ability to continue share repurchases.
  • Share repurchase programs may not lead to sustained stock price appreciation if company fundamentals deteriorate.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026